Integral Diagnostics Limited

ASX:IDX Stock Report

Market Cap: AU$720.5m

Integral Diagnostics Valuation

Is IDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDX (A$3.08) is trading below our estimate of fair value (A$18.71)

Significantly Below Fair Value: IDX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDX?

Key metric: As IDX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IDX. This is calculated by dividing IDX's market cap by their current revenue.
What is IDX's PS Ratio?
PS Ratio1.5x
SalesAU$469.70m
Market CapAU$720.46m

Price to Sales Ratio vs Peers

How does IDX's PS Ratio compare to its peers?

The above table shows the PS ratio for IDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.1x
ACL Australian Clinical Labs
1x4.7%AU$683.3m
CAJ Capitol Health
1.7x6.4%AU$405.1m
HLS Healius
0.6x-4.2%AU$969.4m
HLA Healthia
1xn/aAU$252.1m
IDX Integral Diagnostics
1.5x6.6%AU$720.5m

Price-To-Sales vs Peers: IDX is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does IDX's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.59m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
IDX 1.5xIndustry Avg. 1.4xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IDX is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Oceanic Healthcare industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is IDX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: IDX is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$3.08
AU$3.16
+2.6%
9.9%AU$3.72AU$2.50n/a11
Nov ’25AU$2.99
AU$3.16
+5.7%
9.9%AU$3.72AU$2.50n/a11
Oct ’25AU$2.98
AU$3.07
+3.1%
8.1%AU$3.40AU$2.50n/a12
Sep ’25AU$2.60
AU$2.98
+14.7%
7.4%AU$3.40AU$2.50n/a12
Aug ’25AU$2.45
AU$2.72
+10.9%
14.1%AU$3.40AU$2.10n/a12
Jul ’25AU$2.59
AU$2.57
-0.8%
16.0%AU$3.40AU$1.85n/a13
Jun ’25AU$2.44
AU$2.50
+2.6%
17.5%AU$3.60AU$1.85n/a16
May ’25AU$2.46
AU$2.49
+1.1%
17.7%AU$3.60AU$1.85n/a16
Apr ’25AU$2.25
AU$2.49
+10.5%
17.7%AU$3.60AU$1.85n/a16
Mar ’25AU$2.24
AU$2.45
+9.2%
17.4%AU$3.60AU$1.85n/a15
Feb ’25AU$1.94
AU$2.40
+24.2%
20.2%AU$3.60AU$1.70n/a15
Jan ’25AU$1.91
AU$2.51
+32.0%
19.2%AU$3.60AU$1.95n/a16
Dec ’24AU$1.71
AU$2.51
+47.0%
19.2%AU$3.60AU$1.95n/a16
Nov ’24AU$2.65
AU$3.30
+24.4%
6.7%AU$3.60AU$2.75AU$2.9916
Oct ’24AU$2.87
AU$3.27
+13.8%
8.2%AU$3.60AU$2.58AU$2.9817
Sep ’24AU$2.92
AU$3.27
+11.9%
8.2%AU$3.60AU$2.58AU$2.6017
Aug ’24AU$2.96
AU$3.23
+9.2%
11.1%AU$3.70AU$2.58AU$2.4517
Jul ’24AU$3.28
AU$3.18
-3.0%
11.3%AU$3.70AU$2.58AU$2.5918
Jun ’24AU$3.27
AU$3.11
-5.0%
10.9%AU$3.60AU$2.58AU$2.4418
May ’24AU$3.19
AU$3.05
-4.4%
10.4%AU$3.60AU$2.58AU$2.4616
Apr ’24AU$2.94
AU$2.97
+1.0%
10.7%AU$3.60AU$2.50AU$2.2516
Mar ’24AU$2.79
AU$3.00
+7.5%
10.2%AU$3.60AU$2.50AU$2.2416
Feb ’24AU$3.17
AU$3.19
+0.8%
14.5%AU$4.05AU$2.55AU$1.9415
Jan ’24AU$2.93
AU$3.15
+7.5%
13.8%AU$4.05AU$2.55AU$1.9115
Dec ’23AU$2.76
AU$3.16
+14.4%
14.0%AU$4.05AU$2.55AU$1.7114
Nov ’23AU$2.63
AU$3.15
+19.9%
12.2%AU$3.90AU$2.55AU$2.6514

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

SDI

AU$127.8m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.08

7D

5.9%

1Y

28.7%

Healius

AU$969.4m

Provides specialty diagnostic services to consumer and practitioners in Australia.

HLS

AU$1.33

7D

-16.1%

1Y

-27.9%

Cogstate

AU$170.9m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.98

7D

2.1%

1Y

-32.5%